Boehringer Ingelheim today announced the launch of its corporate venture capital fund, the Boehringer Ingelheim has launched Venture Fund (BIVF).
Investment plans with Biotech and Start-up companies are set to take place as the BIVF look into ground-breaking therapeutic approaches and technologies to help drive innovation in medical science.
These may include – but are not limited to – new therapeutic concepts including stem cells and RNA silencing as well as new generation vaccines, new generation protein or antibody technologies, new molecular targets and/or first-in-class lead compounds. Disease-related biomarkers would be an additional area of focus.
Prof. Andreas Barner, Chairman of the Board of Managing Directors at Boehringer Ingelheim said “Our investments will extend beyond the current therapeutic area focus of Boehringer Ingelheim and our existing therapeutic approaches and technologies.” “We have extensive drug discovery expertise and can take advantage of knowledge and experience available within our global organisation, but we are aware that there is an entire landscape of novel therapeutic ideas and potentially breakthrough technologies that need to be supported for future patients’ benefit.”
Boehringer Ingelheim has initially committed to invest a total fund volume of ‚ £100 Million with the first investments being made in 2010.
Investment opportunities will be sought, on a worldwide basis.
“By focusing on novel therapeutic concepts and potentially breakthrough technologies, our Venture Fund represents a long-term investment in external innovation” says Dr Michel Pairet, Head of the Boehringer Ingelheim Venture Fund. “Our philosophy is to provide both our expertise and funding to drive innovative ideas from early stages into clinical testing.”
For more information, please click the link below: